PROCEPT BioRobotics
PRCT · NASDAQ · Healthcare
$18.09
$0.41 (-2.27%) today
Market Cap
$1.03B
24h Volume
$16.5M
P/E Ratio
-39.2
52w High
$37.65
52w Low
$16.69
Est. AI Revenue
25%
7-Day Sparkline (Static)
Company facts
Performance
About PROCEPT BioRobotics
PROCEPT BioRobotics is a surgical robotics company focused on urology. Its AquaBeam Robotic System treats benign prostatic hyperplasia, an enlarged prostate, using a robot-guided waterjet. Revenue comes from selling the robot to hospitals plus the handpieces consumed in every procedure.
AI supports the procedure itself: AI surgical planning maps each treatment before it starts, and real-time tissue mapping guides the waterjet during surgery, keeping removal precise and consistent across surgeons.
Founded in 2009 and headquartered in Redwood City, California, PROCEPT trades on the NASDAQ and employs about 890 people under CEO Larry L. Wood.
PROCEPT BioRobotics in the AI buildout
PROCEPT sits in the Robotics & Automation and AI Healthcare layers, putting AI directly into the operating room. Its planning and tissue mapping software is what makes the AquaBeam robot consistent from surgeon to surgeon, so AI is genuinely embedded in the product. The investment story, though, is robotics adoption: it depends on surgeons converting procedures to its system rather than on AI demand broadly. Supercycle scores its AI exposure at 55 out of 100.
PRCT is tracked in Robotics & Automation and AI Healthcare, rated Strategic on the AI Exposure leaderboard.
By the numbers
52-week range
PRCT trades at $18.09, 7% of the way up its 52-week range of $16.69 to $37.65.
Market cap
Market capitalization is $1.03B, with an AI Exposure Score of 55 out of 100.
Next earnings
PROCEPT BioRobotics is next expected to report earnings on November 4, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does PROCEPT BioRobotics do?
PROCEPT makes the AquaBeam Robotic System, a surgical robot that treats enlarged prostate using a guided waterjet. It earns revenue from robot sales to hospitals and from handpieces used in every procedure.
How is PROCEPT exposed to AI?
Through embodied AI in surgery. AI-assisted planning and real-time tissue mapping guide every AquaBeam procedure, though the thesis rests on surgical adoption rather than AI demand broadly. Supercycle rates its AI Exposure Score at 55 out of 100.
What are PROCEPT's main products?
The AquaBeam Robotic System for minimally invasive prostate procedures, AI surgical planning software that maps each treatment, and real-time tissue mapping that guides the waterjet during surgery.
Is PRCT a pure play AI stock?
No. It is a surgical robotics adoption story where AI makes the robot precise and repeatable. An AI Exposure Score of 55 out of 100 reflects strong AI content inside a device-driven thesis.
Where is PROCEPT based and who leads it?
PROCEPT BioRobotics is headquartered in Redwood City, California, and led by CEO Larry L. Wood. Founded in 2009, the company employs about 890 people and trades on the NASDAQ.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.